Avalo Therapeutics, Inc. (AVTX) Free cash flow 2016–2022
Avalo Therapeutics, Inc. (AVTX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$26.8MFY2022 · since FY2016: -$14.6M → -$26.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -$26.8M | +62.2% |
| FY2021 | -$71.0M | -74.9% |
| FY2020 | -$40.6M | -109.3% |
| FY2019 | -$19.4M | -425.3% |
| FY2018 | -$3.7M | -129.4% |
| FY2017 | $12.6M | +185.9% |
| FY2016 | -$14.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice